Search Results - "Wee Ma, Wen"

The role of microbiome in pancreatic cancer by Li, Jenny Jing, Zhu, Mojun, Kashyap, Purna C., Chia, Nicholas, Tran, Nguyen H., McWilliams, Robert R., Bekaii-Saab, Tanios S., Ma, Wen Wee

“…Recent studies of the human microbiome have offered new insights into how the microbiome can impact cancer development and treatment. Specifically, in…”
Get full text

Development of focal adhesion kinase inhibitors in cancer therapy by Ma, Wen Wee

“…Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase implicated in cancer progression, and plays a vital role in integrating environmental signals…”
Get more information

The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer by WEN WEE MA, HIDALGO, Manuel

“…Paclitaxel has wide application in anticancer therapy but was never considered an efficacious agent in pancreatic cancer. A review of the experience with the…”
Get full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine by Von Hoff, Daniel D, Ervin, Thomas, Arena, Francis P, Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A, Ma, Wen Wee, Saleh, Mansoor N, Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K, Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F

“…In this report, the addition of nab-paclitaxel to standard gemcitabine increased the response rate, progression-free survival, and overall survival among…”
Get full text

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer by Alva-Ruiz, Roberto, Yohanathan, Lavanya, Yonkus, Jennifer A., Abdelrahman, Amro M., Gregory, Lindsey A., Halfdanarson, Thorvadur R., Mahipal, Amit, McWilliams, Robert R., Ma, Wen Wee, Hallemeier, Christopher L., Graham, Rondell P., Grotz, Travis E., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Kendrick, Michael L., Truty, Mark J.

“…Background Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA)…”
Get full text

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma by Tella, Sri Harsha, Foster, Nathan, Qian, Shi, Nguyen, Tran, Borad, Mitesh J, McWilliams, Robert R, Alberts, Steven R, Wee Ma, Wen, Chakrabarti, Sakti, Fruth, Briant, Wessling, Jaclynn, Hartgers, Mindy, Washburn, Leslie, Fernandez-Zapico, Martin E, Hogenson, Tara L, Pitot, Henry, Jin, Zhaohui, Mahipal, Amit

“…Abstract Background We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for…”
Get full text

Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer by Xie, Hao, Paradise, Brooke D, Ma, Wen Wee, Fernandez-Zapico, Martin E

“…The Hedgehog/GLI signaling pathway plays an important role in normal embryonic tissue development and has been implicated in the pathogenesis of various human…”
Get full text

FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma by Abdelrahman, Amro M, Goenka, Ajit H, Alva-Ruiz, Roberto, Yonkus, Jennifer A, Leiting, Jennifer L, Graham, Rondell P, Merrell, Kenneth W, Thiels, Cornelius A, Hallemeier, Christopher L, Warner, Susanne G, Haddock, Michael G, Grotz, Travis E, Tran, Nguyen H, Smoot, Rory L, Ma, Wen Wee, Cleary, Sean P, McWilliams, Robert R, Nagorney, David M, Halfdanarson, Thorvardur R, Kendrick, Michael L, Truty, Mark J

“…Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly…”
Get more information

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors by Calvo, Emiliano, Soria, Jean-Charles, Ma, Wen Wee, Wang, Tao, Bahleda, Rastilav, Tolcher, Anthony W, Gernhardt, Diana, O'Connell, Joseph, Millham, Robert, Giri, Nagdeep, Wick, Michael J, Adjei, Alex A, Hidalgo, Manuel

“…This phase I, open-label, single-arm trial assessed the safety and tolerability of dacomitinib-figitumumab combination therapy in patients with advanced solid…”
Get full text

ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer by Alva-Ruiz, Roberto, Yohanathan, Lavanya, Yonkus, Jennifer A., Abdelrahman, Amro M., Gregory, Lindsey A., Halfdanarson, Thorvadur R., Mahipal, Amit, McWilliams, Robert R., Ma, Wen Wee, Hallemeier, Christopher L., Graham, Rondell P., Grotz, Travis E., Smoot, Rory L., Cleary, Sean P., Nagorney, David M., Kendrick, Michael L., Truty, Mark J.

Get full text

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy by MA, Wen Wee, JACENE, Heather, HIDALGO, Manuel, SONG, Dongweon, VILARDELL, Felip, MESSERSMITH, Wells A, LAHERU, Dan, WAHL, Richard, ENDRES, Chris, JIMENO, Antonio, POMPER, Martin G

“…Positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG-PET) has increasingly been used to evaluate the efficacy of anticancer agents. We…”
Get full text

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers by Ma, Wen Wee, Zhu, Mojun, Lam, Elaine T., Diamond, Jennifer R., Dy, Grace K., Fisher, George A., Goff, Laura Williams, Alberts, Steven, Bui, Lynne A., Sanghal, Akhil, Kothekar, Mudgal, Khopade, Ajay, Chimote, Geetanjali, Faulkner, Robert, Eckhardt, S. Gail, Adjei, Alex A., Jimeno, Antonio

“…Purpose Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study…”
Get full text

Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy by Choi, Daheui, Gonzalez‐Suarez, Alan M., Dumbrava, Mihai G., Medlyn, Michael, Hoyos‐Vega, Jose M., Cichocki, Frank, Miller, Jeffrey S., Ding, Li, Zhu, Mojun, Stybayeva, Gulnaz, Gaspar‐Maia, Alexandre, Billadeau, Daniel D., Ma, Wen Wee, Revzin, Alexander

“…Patient‐derived cancer organoids (PDOs) hold considerable promise for personalizing therapy selection and improving patient outcomes. However, it is…”
Get full text

Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation by Shahab, Danish, MD, Gabriel, Emmanuel, MD, PhD, Attwood, Kristopher, PhD, Ma, Wen Wee, MBBS, Francescutti, Valerie, MD, Nurkin, Steven, MD, Boland, Patrick M., MD

“…Abstract Background In locally advanced rectal adenocarcinoma (LARC), 15-20% of patients treated with neoadjuvant chemoradiation (nCRT) achieve a pathologic…”
Get full text

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer by WEN WEE MA, MESSERSMITH, Wells A, JIMENO, Antonio, DY, Grace K, WEEKES, Colin D, WHITWORTH, Amy, REN, Chen, MANIAR, Manoj, WILHELM, Francois, ECKHARDT, S. Gail, ADJEI, Alex A

“…Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor…”
Get full text

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer by Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Wee Ma, Wen, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Shiansong Li, Jack, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David

Get full text

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours by Devriese, Lot A., Koch, Kevin M., Mergui-Roelvink, Marja, Matthys, Gemma M., Ma, Wen Wee, Robidoux, Andre, Stephenson, Joe J., Chu, Quincy S. C., Orford, Keith W., Cartee, Leanne, Botbyl, Jeff, Arya, Nikita, Schellens, Jan H. M.

“…Summary Aim To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe…”
Get full text

Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9 by Kowalchuk, Roman O, Lester, Scott C, Graham, Rondell P, Harmsen, William S, Zhang, Lizhi, Halfdanarson, Thorvardur R, Smoot, Rory L, Gits, Hunter C, Ma, Wen Wee, Owen, Dawn, Mahipal, Amit, Miller, Robert C, Wittich, Michelle A Neben, Cleary, Sean P, McWilliams, Robert R, Haddock, Michael G, Hallemeier, Christopher L, Truty, Mark J, Merrell, Kenneth W

“…We evaluated preoperative CA 19-9 levels in patients with resected pancreatic cancer to analyze whether they were predictive of clinical outcomes and could…”
Get full text

729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors by Lee, Jeeyun, Cho, Byoung Chul, Lee, Jae Lyun, Lee, Jung-Yun, Campian, Jian L, Zhao, Yujie, Seetharam, Mahesh, Adjei, Alex A, Ma, Wen Wee, Chae, Dongwoo, Yun, Nari, Lee, Woosun, Lee, Wooyul, Park, Sosun, Seo, Bochan, Lee, Kyungwha, Park, Chong Woo, Jang, Myoung Ho

“…BackgroundGI-102 (CD80-IL2v3) is a novel immunocytokine, designed to direct IL-2v to tumor and immune cells. IL-2v3 of GI-102 is designed to abolish the…”
Get full text

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors by He, Jimmy, Jackson, Christopher G. C. A., Deva, Sanjeev, Hung, Tak, Clarke, Katriona, Segelov, Eva, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Ma, Wen Wee, Kramer, Douglas, Chan, Wing‐Kai, Kwan, Rudolf, Cutler, David, Zhi, Jay

“…Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate…”
Get full text